Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
| Autor: | Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., Elisaf, M. S. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Clinical Trials as Topic Lipids/blood Triazoles/administration & dosage/adverse effects/*therapeutic use Blood Pressure/drug effects Diabetes Mellitus Type 2/*drug therapy Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use Pregnancy Pyrazines/administration & dosage/adverse effects/*therapeutic use Humans Dipeptidyl-Peptidase IV Inhibitors/therapeutic use Drug Interactions Drug Therapy Combination Female Child Aged |
| Popis: | BACKGROUND: Sitagliptin is a novel agent for the treatment of type 2 diabetes either as monotherapy or in combination with metformin or a thiazolidinedione. OBJECTIVE: To review the efficacy and safety of sitagliptin in clinical trials and comment on drug interactions and safety issues arising from its use. METHODS: Relevant articles were identified through a PubMed search (up to May 2008). RESULTS/CONCLUSIONS: Sitagliptin either used alone or in combination with other hypoglycemic agents has a favorable glucose-lowering effect and safety profile. It has been associated with few side effects, mainly involving the gastrointestinal system and with a low incidence of hypoglycemia, while it generally demonstrated a neutral effect on body weight. Sitagliptin is a safe alternative or complementary option for patients with type 2 diabetes who do not reach the recommended glycosylated hemoglobin level with lifestyle interventions and/or current oral antidiabetic agents. Expert Opin Pharmacother |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|